Cytokeratin 7 as a predictive factor for response to concommitant radiochemotherapy for locally advanced cervical cancer: A preliminary study

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 177-181

  Lambaudie, Eric ^a,b   Chereau, Elisabeth ^a   Pouget, Nicolas ^a   Thomassin, Jeanne ^a,b   Minsat, Mathieu ^a   Charafe Jauffret, Emmanuelle ^a,b   Jacquemier, Jocelyne ^b   Houvenaeghel, Gilles ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Advanced cervical cancer; Biomarkers; CK7; Radiochemotherapy; Survival

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 ANTIGEN; CISPLATIN; CYTOKERATIN 7; HERMES ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; KI 67 ANTIGEN; PROTEIN P63; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PREDICTION; PROCEDURES; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; ADENOCARCINOMA; ADVANCED CERVICAL CANCER; CK7; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MORTALITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL; SURVIVAL RATE; UTERINE CERVIX TUMOR;

ADVANCED CERVICAL CANCER; BIOMARKERS; CK7; RADIOCHEMOTHERAPY; SURVIVAL;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-7; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84897025429     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vale CL, Tierney JF, Davidson SE, Drinkwater KJ and Symonds P: Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin Oncol 22: 590-601, 2010.
2. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010 Jan 20;(1): CD008285.
3. Ferrandina G, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, Macchia G, Morganti AG, Cellini N and Scambia G: Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol 119: 404-410, 2010.
4. Morice P, Rouanet P, Rey A, Romestaing P, Houvenaeghel G, Boulanger JC, Leveque J, Cowen D, Mathevet P, Malhaire JP, Magnin G, Fondrinier E, Berille J and Haie-Meder C: Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist 17: 64-71, 2012.
5. Houvenaeghel G, Lelievre L, Buttarelli M, Jacquemier J, Carcopino X, Viens P and Gonzague-Casabianca L: Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. Eur J Surg Oncol 33: 498-503, 2007.
6. Touboul C, Uzan C, Mauguen A, Gouy S, Rey A, Pautier P, Lhommé C, Duvillard P, Haie-Meder C and Morice P: Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer. Oncologist 15: 405-415, 2010.
7. Jordan CT, Guzman ML and Noble M. Cancer stem cells. N Engl J Med 355: 1253-1261, 2006.
8. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P and Wicha MS: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16: 45-55, 2010.
9. Chen YC, Chang CJ, Hsu HS, Chen YW, Tai LK, Tseng LM, Chiou GY, Chang SC, Kao SY, Chiou SH and Lo WL: Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 46: 158-165, 2010.
10. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15, 2006.
11. Costa MJ, McIlnay KR and Trelford J: Cervical carcinoma with glandular differentiation: histological evaluation predicts disease recurrence in clinical stage I or II patients. Hum Pathol 26: 829-837, 1995.
12. Smedts F, Ramaekers FC and Vooijs PG: The dynamics of keratin expression in malignant transformation of cervical epithelium: a review. Obstet Gynecol 82: 465,1993.
13. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P and Mihatsch MJ: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178: 437-441, 1996.
14. Feng W, Xiao J, Zhang Z, Rosen DG, Brown RE, Liu J and Duan X. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod Pathol 20: 961-966, 2007.
15. Pillai MR, Jayaprakash PG and Nair MK: Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 124: 456-461, 1998.
16. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, Kage M, Hori D and Kamura T: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 101: 967-972, 2009.
17. Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, Van den Eynde B, Birnbaum D, Olive D and Xerri L: High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 130: 96-104, 2012.
18. Carcopino X, Houvenaeghel G, Buttarelli M, Esterni B, Tallet A, Goncalves A and Jacquemier J: Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy. Eur J Surg Oncol 34: 569-575, 2008.
19. Houvenaeghel G, Carcopino X and Tallet A: Tumours of the cervix. Tumour of the uterus. Rev Prat 57: 677-686, 2007.
20. Classe JM, Rauch P, Rodier JF, Morice P, Stoeckle E, Lasry S, Houvenaeghel G; Groupe des Chirurgiens de Centre de Lutte Contre le Cancer. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol 102: 523-529, 2006.
21. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O and Saito S: Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 98: 874-881, 2007.
22. Ladoire S, Arnould L, Mignot G, Coudert B, Rébé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P and Ghiringhelli F: Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125: 65-72, 2011.
23. Kobayashi A, Weinberg V, Darragh T and Smith-McCune K: Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 1: 412-420, 2008.
24. +/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14: 2028-2035, 2008.
25. Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K and Kikkawa F: Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14: 7251-7259, 2008.
26. Dunn GP, Old LJ and Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2): 137-148, 2004.
27. Katz JB, Muller AJ and Prendergast GC: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222: 206-221, 2008.
28. Nai MM, Yin RT, Xie C, Kang DY and Tang XL: The expression of RhoC and Ki67 in cervical intraepithelial neoplasia and squamous carcinoma of cervix. Sichuan Da Xue Xue Bao Yi Xue Ban 40: 236-239, 2009.
29. Moll R: Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers. 9:63-9,1994.
30. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X and Liu J: ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22: 817-823, 2009.